From Toad “Venom” to Potential Antidepressant: 5-MeO-DMT shifts from underground use to early clinical trials

5-MeO-DMT, found in secretions often called “toad venom,” is framed as an ultra-short acting serotonergic psychedelic that may deliver rapid antidepressant effects. The article traces how toad use moved from underground psychedelic and neo-shamanic communities, amplified by celebrity stories (including Mike Tyson), into mainstream attention and early pharmaceutical interest. It also notes environmental and animal welfare concerns as demand increased, alongside the cultural reframing of “toad medicine” and “the God molecule.” In controlled research settings, purified synthetic 5-MeO-DMT is described as being generally well tolerated, with transient side effects and brief intense acute experiences. Early clinical programs (including vaporized intranasal fixed dose approaches) are presented as showing rapid depressive symptom reductions, potentially within days, but the author emphasizes that Phase 3 trials are needed for safety, durability, remission rates, and broader targets like PTSD, postpartum depression, and substance use disorders.